NCT02685826 · BASELINE
Baseline characteristics
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- denoms
- counts
- group Id
- BG000
- value
- 25
- group Id
- BG001
- value
- 10
- group Id
- BG002
- value
- 21
- group Id
- BG003
- value
- 56
- units
- Participants
- groups
- description
- High risk, transplant non-eligible \[TNE\], newly diagnosed multiple myeloma (NDMM) participants who were administered • Intravenous (IV) durvalumab at 1500 mg on Day 1 of each 28-day cycle • Oral lenalidomide (LEN) 25 mg/day (adjust per the creatinine clearance \[CrCl\] value) on Days 1 to 21 of each 28-day treatment cycle • Oral dexamethasone (dex) 40 mg/day (≤ 75 years old) or 20 mg/day (\> 75 years old) on Days 1, 8, 15, and 22 of each 28-day cycle.
- id
- BG000
- title
- Cohort A: High Risk, TNE
- description
- \>= 65 years old, transplant non-eligible \[TNE\], newly diagnosed multiple myeloma (NDMM) participants who were not high risk were administered • Intravenous (IV) durvalumab at 1500 mg on Day 1 of each 28-day cycle • Oral lenalidomide (LEN) 25 mg/day (adjust per the creatinine clearance \[CrCl\] value) on Days 1 to 21 of each 28-day treatment cycle • Oral dexamethasone (dex) 40 mg/day (≤ 75 years old) or 20 mg/day (\> 75 years old) on Days 1, 8, 15, and 22 of each 28-day cycle, up to 12 cycles.
- id
- BG001
- title
- Cohort B: >=65 Years Old, TNE
- description
- High risk, post-transplant NDMM participants were administered the following as maintenance therapy: • Intravenous (IV) durvalumab at 1500 mg on Day 1 of each 28-day cycle • Oral lenalidomide (LEN) 10 mg/day on Days 1 to 21 of each 28-day treatment cycle.
- id
- BG002
- title
- Cohort C: High Risk, Post-transplant
- description
- Total of all reporting groups
- id
- BG003
- title
- Total
- measures
- classes
- categories
- measurements
- group Id
- BG000
- spread
- 4.17
- value
- 75.4
- group Id
- BG001
- spread
- 5.25
- value
- 72.5
- group Id
- BG002
- spread
- 7.52
- value
- 59.6
- group Id
- BG003
- spread
- 9.33
- value
- 68.98
- denoms
- counts
- group Id
- BG000
- value
- 25
- group Id
- BG001
- value
- 10
- group Id
- BG002
- value
- 21
- group Id
- BG003
- value
- 56
- units
- Participants
- dispersion Type
- STANDARD_DEVIATION
- param Type
- MEAN
- title
- Age, Continuous
- unit Of Measure
- years
- classes
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 17
- group Id
- BG003
- value
- 17
- denoms
- counts
- group Id
- BG000
- value
- 25
- group Id
- BG001
- value
- 10
- group Id
- BG002
- value
- 21
- group Id
- BG003
- value
- 56
- units
- Participants
- title
- <=65 years
- categories
- measurements
- group Id
- BG000
- value
- 25
- group Id
- BG001
- value
- 10
- group Id
- BG002
- value
- 4
- group Id
- BG003
- value
- 39
- denoms
- counts
- group Id
- BG000
- value
- 25
- group Id
- BG001
- value
- 10
- group Id
- BG002
- value
- 21
- group Id
- BG003
- value
- 56
- units
- Participants
- title
- >65 years
- categories
- measurements
- group Id
- BG000
- value
- 12
- group Id
- BG001
- value
- 7
- group Id
- BG002
- value
- 20
- group Id
- BG003
- value
- 39
- denoms
- counts
- group Id
- BG000
- value
- 25
- group Id
- BG001
- value
- 10
- group Id
- BG002
- value
- 21
- group Id
- BG003
- value
- 56
- units
- Participants
- title
- <=75 years
- categories
- measurements
- group Id
- BG000
- value
- 13
- group Id
- BG001
- value
- 3
- group Id
- BG002
- value
- 1
- group Id
- BG003
- value
- 17
- denoms
- counts
- group Id
- BG000
- value
- 25
- group Id
- BG001
- value
- 10
- group Id
- BG002
- value
- 21
- group Id
- BG003
- value
- 56
- units
- Participants
- title
- >75 years
- param Type
- NUMBER
- title
- Age, Customized
- unit Of Measure
- participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 15
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 4
- group Id
- BG003
- value
- 19
- title
- Female
- measurements
- group Id
- BG000
- value
- 10
- group Id
- BG001
- value
- 10
- group Id
- BG002
- value
- 17
- group Id
- BG003
- value
- 37
- title
- Male
- denoms
- counts
- group Id
- BG000
- value
- 25
- group Id
- BG001
- value
- 10
- group Id
- BG002
- value
- 21
- group Id
- BG003
- value
- 56
- units
- Participants
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Sex: Female, Male
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- title
- American Indian or Alaska Native
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 2
- title
- Asian
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- title
- Native Hawaiian or Other Pacific Islander
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 1
- title
- Black or African American
- measurements
- group Id
- BG000
- value
- 21
- group Id
- BG001
- value
- 9
- group Id
- BG002
- value
- 17
- group Id
- BG003
- value
- 47
- title
- White
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- title
- More than one race
- measurements
- group Id
- BG000
- value
- 2
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 4
- group Id
- BG003
- value
- 6
- title
- Unknown or Not Reported
- denoms
- counts
- group Id
- BG000
- value
- 25
- group Id
- BG001
- value
- 10
- group Id
- BG002
- value
- 21
- group Id
- BG003
- value
- 56
- units
- Participants
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Race (NIH/OMB)
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 7
- group Id
- BG001
- value
- 5
- group Id
- BG002
- value
- 13
- group Id
- BG003
- value
- 25
- title
- 0 = Fully Active
- measurements
- group Id
- BG000
- value
- 14
- group Id
- BG001
- value
- 5
- group Id
- BG002
- value
- 8
- group Id
- BG003
- value
- 27
- title
- 1 = Restrictive but ambulatory
- measurements
- group Id
- BG000
- value
- 4
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 4
- title
- 2 = ambulatory but unable to work
- denoms
- counts
- group Id
- BG000
- value
- 25
- group Id
- BG001
- value
- 10
- group Id
- BG002
- value
- 21
- group Id
- BG003
- value
- 56
- units
- Participants
- description
- ECOG performance status is used to assess how a subject's disease is progressing, and how the disease affects the daily living activities and determine appropriate treatment and prognosis. 0 = Fully Active, able to carry on all pre-disease performance without restriction; 1 = Restricted, in physically strenuous activity but ambulatory; 2 = Ambulatory and capable of all self-care; unable to carry out work activities; 3 = Capable of only limited self-care, confined to bed or chair \>50% of waking hours; 4 = Completely Disabled, cannot carry on any self-care.
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Eastern Cooperative Oncology Group (ECOG) Performance Status
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 2
- group Id
- BG001
- value
- 5
- group Id
- BG002
- value
- 3
- group Id
- BG003
- value
- 10
- title
- Stage I
- measurements
- group Id
- BG000
- value
- 7
- group Id
- BG001
- value
- 5
- group Id
- BG002
- value
- 7
- group Id
- BG003
- value
- 19
- title
- Stage II
- measurements
- group Id
- BG000
- value
- 13
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 11
- group Id
- BG003
- value
- 24
- title
- Stage III
- measurements
- group Id
- BG000
- value
- 3
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 3
- title
- Missing
- denoms
- counts
- group Id
- BG000
- value
- 25
- group Id
- BG001
- value
- 10
- group Id
- BG002
- value
- 21
- group Id
- BG003
- value
- 56
- units
- Participants
- description
- Multiple myeloma has three stages, which are known as stage I, stage II and stage III. Staging in myeloma is done on the basis of the value of serum albumin and beta-2 microglobulin level. Stage I has the best prognosis and stage III the worst prognosis.
- param Type
- COUNT_OF_PARTICIPANTS
- title
- International Staging System (ISS) for MM at Diagnosis
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 17
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 2
- group Id
- BG003
- value
- 19
- title
- Yes
- measurements
- group Id
- BG000
- value
- 8
- group Id
- BG001
- value
- 10
- group Id
- BG002
- value
- 19
- group Id
- BG003
- value
- 37
- title
- No
- denoms
- counts
- group Id
- BG000
- value
- 25
- group Id
- BG001
- value
- 10
- group Id
- BG002
- value
- 21
- group Id
- BG003
- value
- 56
- units
- Participants
- param Type
- COUNT_OF_PARTICIPANTS
- title
- High-Risk Cytogenetic Abnormalities at Baseline
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG002
- value
- 21
- group Id
- BG003
- value
- 21
- title
- Positive
- measurements
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- title
- Negative
- denoms
- counts
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 21
- group Id
- BG003
- value
- 21
- units
- Participants
- description
- MRD status is either positive or negative. Positive was defined as more than 1 malignant cells in 10\^5 cells as measured by the ClonoSIGHT(TM) NGS (next generation sequencing) assay of a bone marrow aspirate sample.
- param Type
- COUNT_OF_PARTICIPANTS
- population Description
- Data was collected for Cohort C only.
- title
- Minimal Residual Disease (MRD) Status
- unit Of Measure
- Participants
- population Description
- Full analysis population. The Full Analysis Population (FAS) is defined as all participants who are enrolled (signed the inform consent form and meet all eligibility criteria) in the study. Participants are analyzed according to the initial cohort actually assigned.
Complete source fields
- denoms
- counts
- group Id
- BG000
- value
- 25
- group Id
- BG001
- value
- 10
- group Id
- BG002
- value
- 21
- group Id
- BG003
- value
- 56
- units
- Participants
- groups
- description
- High risk, transplant non-eligible \[TNE\], newly diagnosed multiple myeloma (NDMM) participants who were administered • Intravenous (IV) durvalumab at 1500 mg on Day 1 of each 28-day cycle • Oral lenalidomide (LEN) 25 mg/day (adjust per the creatinine clearance \[CrCl\] value) on Days 1 to 21 of each 28-day treatment cycle • Oral dexamethasone (dex) 40 mg/day (≤ 75 years old) or 20 mg/day (\> 75 years old) on Days 1, 8, 15, and 22 of each 28-day cycle.
- id
- BG000
- title
- Cohort A: High Risk, TNE
- description
- \>= 65 years old, transplant non-eligible \[TNE\], newly diagnosed multiple myeloma (NDMM) participants who were not high risk were administered • Intravenous (IV) durvalumab at 1500 mg on Day 1 of each 28-day cycle • Oral lenalidomide (LEN) 25 mg/day (adjust per the creatinine clearance \[CrCl\] value) on Days 1 to 21 of each 28-day treatment cycle • Oral dexamethasone (dex) 40 mg/day (≤ 75 years old) or 20 mg/day (\> 75 years old) on Days 1, 8, 15, and 22 of each 28-day cycle, up to 12 cycles.
- id
- BG001
- title
- Cohort B: >=65 Years Old, TNE
- description
- High risk, post-transplant NDMM participants were administered the following as maintenance therapy: • Intravenous (IV) durvalumab at 1500 mg on Day 1 of each 28-day cycle • Oral lenalidomide (LEN) 10 mg/day on Days 1 to 21 of each 28-day treatment cycle.
- id
- BG002
- title
- Cohort C: High Risk, Post-transplant
- description
- Total of all reporting groups
- id
- BG003
- title
- Total
- measures
- classes
- categories
- measurements
- group Id
- BG000
- spread
- 4.17
- value
- 75.4
- group Id
- BG001
- spread
- 5.25
- value
- 72.5
- group Id
- BG002
- spread
- 7.52
- value
- 59.6
- group Id
- BG003
- spread
- 9.33
- value
- 68.98
- denoms
- counts
- group Id
- BG000
- value
- 25
- group Id
- BG001
- value
- 10
- group Id
- BG002
- value
- 21
- group Id
- BG003
- value
- 56
- units
- Participants
- dispersion Type
- STANDARD_DEVIATION
- param Type
- MEAN
- title
- Age, Continuous
- unit Of Measure
- years
- classes
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 17
- group Id
- BG003
- value
- 17
- denoms
- counts
- group Id
- BG000
- value
- 25
- group Id
- BG001
- value
- 10
- group Id
- BG002
- value
- 21
- group Id
- BG003
- value
- 56
- units
- Participants
- title
- <=65 years
- categories
- measurements
- group Id
- BG000
- value
- 25
- group Id
- BG001
- value
- 10
- group Id
- BG002
- value
- 4
- group Id
- BG003
- value
- 39
- denoms
- counts
- group Id
- BG000
- value
- 25
- group Id
- BG001
- value
- 10
- group Id
- BG002
- value
- 21
- group Id
- BG003
- value
- 56
- units
- Participants
- title
- >65 years
- categories
- measurements
- group Id
- BG000
- value
- 12
- group Id
- BG001
- value
- 7
- group Id
- BG002
- value
- 20
- group Id
- BG003
- value
- 39
- denoms
- counts
- group Id
- BG000
- value
- 25
- group Id
- BG001
- value
- 10
- group Id
- BG002
- value
- 21
- group Id
- BG003
- value
- 56
- units
- Participants
- title
- <=75 years
- categories
- measurements
- group Id
- BG000
- value
- 13
- group Id
- BG001
- value
- 3
- group Id
- BG002
- value
- 1
- group Id
- BG003
- value
- 17
- denoms
- counts
- group Id
- BG000
- value
- 25
- group Id
- BG001
- value
- 10
- group Id
- BG002
- value
- 21
- group Id
- BG003
- value
- 56
- units
- Participants
- title
- >75 years
- param Type
- NUMBER
- title
- Age, Customized
- unit Of Measure
- participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 15
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 4
- group Id
- BG003
- value
- 19
- title
- Female
- measurements
- group Id
- BG000
- value
- 10
- group Id
- BG001
- value
- 10
- group Id
- BG002
- value
- 17
- group Id
- BG003
- value
- 37
- title
- Male
- denoms
- counts
- group Id
- BG000
- value
- 25
- group Id
- BG001
- value
- 10
- group Id
- BG002
- value
- 21
- group Id
- BG003
- value
- 56
- units
- Participants
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Sex: Female, Male
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- title
- American Indian or Alaska Native
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 2
- title
- Asian
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- title
- Native Hawaiian or Other Pacific Islander
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 1
- title
- Black or African American
- measurements
- group Id
- BG000
- value
- 21
- group Id
- BG001
- value
- 9
- group Id
- BG002
- value
- 17
- group Id
- BG003
- value
- 47
- title
- White
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- title
- More than one race
- measurements
- group Id
- BG000
- value
- 2
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 4
- group Id
- BG003
- value
- 6
- title
- Unknown or Not Reported
- denoms
- counts
- group Id
- BG000
- value
- 25
- group Id
- BG001
- value
- 10
- group Id
- BG002
- value
- 21
- group Id
- BG003
- value
- 56
- units
- Participants
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Race (NIH/OMB)
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 7
- group Id
- BG001
- value
- 5
- group Id
- BG002
- value
- 13
- group Id
- BG003
- value
- 25
- title
- 0 = Fully Active
- measurements
- group Id
- BG000
- value
- 14
- group Id
- BG001
- value
- 5
- group Id
- BG002
- value
- 8
- group Id
- BG003
- value
- 27
- title
- 1 = Restrictive but ambulatory
- measurements
- group Id
- BG000
- value
- 4
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 4
- title
- 2 = ambulatory but unable to work
- denoms
- counts
- group Id
- BG000
- value
- 25
- group Id
- BG001
- value
- 10
- group Id
- BG002
- value
- 21
- group Id
- BG003
- value
- 56
- units
- Participants
- description
- ECOG performance status is used to assess how a subject's disease is progressing, and how the disease affects the daily living activities and determine appropriate treatment and prognosis. 0 = Fully Active, able to carry on all pre-disease performance without restriction; 1 = Restricted, in physically strenuous activity but ambulatory; 2 = Ambulatory and capable of all self-care; unable to carry out work activities; 3 = Capable of only limited self-care, confined to bed or chair \>50% of waking hours; 4 = Completely Disabled, cannot carry on any self-care.
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Eastern Cooperative Oncology Group (ECOG) Performance Status
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 2
- group Id
- BG001
- value
- 5
- group Id
- BG002
- value
- 3
- group Id
- BG003
- value
- 10
- title
- Stage I
- measurements
- group Id
- BG000
- value
- 7
- group Id
- BG001
- value
- 5
- group Id
- BG002
- value
- 7
- group Id
- BG003
- value
- 19
- title
- Stage II
- measurements
- group Id
- BG000
- value
- 13
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 11
- group Id
- BG003
- value
- 24
- title
- Stage III
- measurements
- group Id
- BG000
- value
- 3
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 3
- title
- Missing
- denoms
- counts
- group Id
- BG000
- value
- 25
- group Id
- BG001
- value
- 10
- group Id
- BG002
- value
- 21
- group Id
- BG003
- value
- 56
- units
- Participants
- description
- Multiple myeloma has three stages, which are known as stage I, stage II and stage III. Staging in myeloma is done on the basis of the value of serum albumin and beta-2 microglobulin level. Stage I has the best prognosis and stage III the worst prognosis.
- param Type
- COUNT_OF_PARTICIPANTS
- title
- International Staging System (ISS) for MM at Diagnosis
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 17
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 2
- group Id
- BG003
- value
- 19
- title
- Yes
- measurements
- group Id
- BG000
- value
- 8
- group Id
- BG001
- value
- 10
- group Id
- BG002
- value
- 19
- group Id
- BG003
- value
- 37
- title
- No
- denoms
- counts
- group Id
- BG000
- value
- 25
- group Id
- BG001
- value
- 10
- group Id
- BG002
- value
- 21
- group Id
- BG003
- value
- 56
- units
- Participants
- param Type
- COUNT_OF_PARTICIPANTS
- title
- High-Risk Cytogenetic Abnormalities at Baseline
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG002
- value
- 21
- group Id
- BG003
- value
- 21
- title
- Positive
- measurements
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- title
- Negative
- denoms
- counts
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 21
- group Id
- BG003
- value
- 21
- units
- Participants
- description
- MRD status is either positive or negative. Positive was defined as more than 1 malignant cells in 10\^5 cells as measured by the ClonoSIGHT(TM) NGS (next generation sequencing) assay of a bone marrow aspirate sample.
- param Type
- COUNT_OF_PARTICIPANTS
- population Description
- Data was collected for Cohort C only.
- title
- Minimal Residual Disease (MRD) Status
- unit Of Measure
- Participants
- population Description
- Full analysis population. The Full Analysis Population (FAS) is defined as all participants who are enrolled (signed the inform consent form and meet all eligibility criteria) in the study. Participants are analyzed according to the initial cohort actually assigned.
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice
Triangle